HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer
Open Access
- 18 June 2020
- Vol. 12 (6), 1623
- https://doi.org/10.3390/cancers12061623
Abstract
The prognostic value of human leukocyte antigen (HLA) class I molecules in prostate cancer (PCa) remains unclear. Herein, we investigated the prognostic relevance of the most frequently expressed HLA-A alleles in Greece (A*02:01 and HLA-A*24:02) in de novo metastatic hormone-sensitive PCa (mPCa), which is a rare and aggressive disease characterized by a rapid progression to castration-resistance (CR) and poor overall survival (OS), contributing to almost 50% of PCa-related deaths. We identified 56 patients who had either progressed to CR (these patients were retrospectively analyzed for the time to the progression of CR and prospectively for OS) or had at least three months’ follow-up postdiagnosis without CR progression and, thus, were prospectively analyzed for both CR and OS. Patients expressing HLA-A*02:01 showed poor clinical outcomes vs. HLA-A*02:01−negative patients. HLA-A*24:02−positive patients progressed slower to CR and had increased OS. Homozygous HLA-A*02:01 patients progressed severely to CR, with very short OS. Multivariate analyses ascribed to both HLA alleles significant prognostic values for the time to progression (TTP) to CR and OS. The presence of HLA-A*02:01 and HLA-A*24:02 alleles in de novo mPCa patients are significantly and independently associated with unfavorable or favorable clinical outcomes, respectively, suggesting their possible prognostic relevance for treatment decision-making in the context of precision medicine.This publication has 48 references indexed in Scilit:
- No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year periodCancer, 2013
- The complexity of prostate cancer: genomic alterations and heterogeneityNature Reviews Urology, 2012
- Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancerCancer Immunology, Immunotherapy, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene, 2008
- A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study AnalysisClinical Cancer Research, 2007
- Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific ImmunityCancer Research, 2006
- Correlation between HLA-A2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality RatesMedical Oncology, 2004
- Multiple mechanisms underlie HLA dysregulation in cervical cancerTissue Antigens, 2000
- Population Biology of Antigen Presentation by MHC Class I MoleculesScience, 1996